| DMXAA treatment | Tumor area (mm2) | Total CD45+ cells | Cells for scRNA-seq | Cells recovered for analysis |
|---|---|---|---|---|
| 7 d | ||||
| + | 38.5 | 550,000 | 16,000 | 6,959 |
| + | 45 | 425,000 | 16,000 | 9,842 |
| + | 33.75 | 225,000 | 16,000 | 3,989 |
| − | 59.5 | 162,500 | 16,000 | 11,842 |
| − | 55.25 | 212,500 | 16,000 | 8,541 |
| − | 63 | 175,000 | 16,000 | 8,246 |
| 10 d | ||||
| + | 45 | 195,000 | 16,000 | 8,044 |
| + | 41.25 | 195,000 | 16,000 | 11,786 |
| DMXAA treatment | Tumor area (mm2) | Total CD45+ cells | Cells for scRNA-seq | Cells recovered for analysis |
|---|---|---|---|---|
| + | 38.5 | 550,000 | 16,000 | 6,959 |
| + | 45 | 425,000 | 16,000 | 9,842 |
| + | 33.75 | 225,000 | 16,000 | 3,989 |
| − | 59.5 | 162,500 | 16,000 | 11,842 |
| − | 55.25 | 212,500 | 16,000 | 8,541 |
| − | 63 | 175,000 | 16,000 | 8,246 |
| + | 45 | 195,000 | 16,000 | 8,044 |
| + | 41.25 | 195,000 | 16,000 | 11,786 |
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.